Category: Reports and analyses

Archive

Categories

Interviews with leading Life Sciences companies: J-Pharma
by Venture Valuation
May 26, 2023
Venture Valuation/Biotechgate Partners with ALLIS-NA: Launch of Member Directory
by Venture Valuation
May 11, 2023
Interviews with leading Life Sciences companies: Aipore
by Venture Valuation
February 10, 2023
Interviews with leading Life Sciences companies: Varinos Inc.
by Venture Valuation
October 6, 2022
The World’s First Drug Discovery Platform Using Quantum Computing – POLARISqb
by Venture Valuation
June 28, 2022

Socials Share

Preview. Site Selection for Life Sciences Companies: Cluster Report 2015

Venture Valuation

Feb 26, 2015

Venture Valuation presented a preview of its new report together with KPMG “Site Selection for […]
Know More
Biotech Product Valuation – Setting a Price for Acquisitions

Venture Valuation

Nov 26, 2014

Big acquisitions like the recent purchase by Roche, Switzerland of Intermune, USA or AbbVie‘s successful […]
Know More
How to raise sufficient funds for Biotechs?

Venture Valuation

Sep 25, 2014

September 2014: Financing is an ongoing challenge for all Biotech companies. Without sufficient resources, products […]
Know More
The premium of a big pharma license deal

Venture Valuation

Jul 30, 2014

Venture Valuation recently published an article in Nature Biotechnology 32, 617–619, (2014) based on data […]
Know More
Soccer and Pharma/BIOtech

Venture Valuation

Jun 23, 2014

Marketing alliances between well-known brand names and consumer products have long been a tradition for […]
Know More
Is Orphan saving Biotech?

Venture Valuation

May 28, 2014

Orphan drugs have been en vogue for a while. However, in the last quarter there […]
Know More
Who is investing and who is not?

Venture Valuation

Apr 29, 2014

Are you wondering what investors still have money and are investing? At Biotechgate we are […]
Know More
What is the impact of Novartis transformation on biotech industry?

Venture Valuation

Apr 29, 2014

With the announcement of the portfolio transformation of Novartis this month, we believe this will […]
Know More
Early stage VC funding in the US more difficult than ever

Venture Valuation

Mar 26, 2014

Even with the public biotech was just at an all time high, VCs in the […]
Know More
Global, Early-Stage Investors in Emerging Life Science Companies

Venture Valuation

Feb 25, 2014

Does it make sense for a life science fundraising executive in Europe to look internationally […]
Know More